Whole-genome DNA methylation profiling of 152 pediatric AML patients

Genome-wide CpG-island methylation profiling on pediatric AML samples was performed to identify specific methylation patterns discriminating particular AML subgroups from the rest of AML samples based on the methylation profile. Genomic DNA from pediatric AML material representing different cytogenetic subgroups was used: inv(16)(p13;q22) (CBFB-MYH11), MLL-rearrangement, t(8;21)(q22;q22) (RUNX1-RUNX1T1), t(15;17)(q24;q21) (PML-RARA), t(8;16)(p11;p13) (KAT6A-CREBBP), t(5;11)(q35;p15.5) (NUP98-NSD1) or C/EPBα (double mutation) and NPM1 mutations and CN AMLs. AML samples were enriched for ≥80% leukemic cells.